Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Human papillomavirus (HPV) infections as risk factors for cytological and histological abnormalities in baseline PAP smear-negative women followed-up for 2 years in the LAMS study.
Gontijo RC, Derchain SF, Roteli-Martins C, Bragança JF, Sarian LO, Morais SS, Maeda MY, Longatto-Filho A, Syrjänen KJ. Gontijo RC, et al. Among authors: sarian lo. Eur J Obstet Gynecol Reprod Biol. 2007 Aug;133(2):239-46. doi: 10.1016/j.ejogrb.2006.05.012. Epub 2006 Jun 30. Eur J Obstet Gynecol Reprod Biol. 2007. PMID: 16814450
Evaluation of visual inspection with acetic acid (VIA), Lugol's iodine (VILI), cervical cytology and HPV testing as cervical screening tools in Latin America. This report refers to partial results from the LAMS (Latin AMerican Screening) study.
Sarian LO, Derchain SF, Naud P, Roteli-Martins C, Longatto-Filho A, Tatti S, Branca M, Erzen M, Serpa-Hammes L, Matos J, Gontijo R, Bragança JF, Lima TP, Maeda MY, Lörincz A, Dores GB, Costa S, Syrjänen S, Syrjänen K. Sarian LO, et al. J Med Screen. 2005;12(3):142-9. doi: 10.1258/0969141054855328. J Med Screen. 2005. PMID: 16156945
Human papillomavirus testing as an optional screening tool in low-resource settings of Latin America: experience from the Latin American Screening study.
Longatto-Filho A, Erzen M, Branca M, Roteli-Martins C, Naud P, Derchain SF, Hammes L, Sarian LO, Bragança JF, Matos J, Gontijo R, Lima T, Maeda MY, Tatti S, Syrjänen S, Dores G, Lörincz A, Syrjänen K. Longatto-Filho A, et al. Among authors: sarian lo. Int J Gynecol Cancer. 2006 May-Jun;16(3):955-62. doi: 10.1111/j.1525-1438.2006.00582.x. Int J Gynecol Cancer. 2006. PMID: 16803469
Safety of screening with Human papillomavirus testing for cervical cancer at three-year intervals in a high-risk population: experience from the LAMS study.
Derchain SF, Sarian LO, Naud P, Roteli-Martins C, Longatto-Filho A, Tatti S, Branca M, Erzen M, Serpa-Hammes L, Matos J, Gontijo RC, Bragança JF, Lima TP, Maeda MY, Lörincz A, Dores GB, Costa S, Syrjänen S, Syrjänen K. Derchain SF, et al. Among authors: sarian lo. J Med Screen. 2008;15(2):97-104. doi: 10.1258/jms.2008.007061. J Med Screen. 2008. PMID: 18573778
Covariates of high-risk human papillomavirus (HPV) infections are distinct for incident CIN1, CIN2 and CIN3 as disclosed by competing-risks regression models.
Syrjänen K, Shabalova I, Sarian L, Naud P, Longatto-Filho A, Derchain S, Kozachenko V, Zakharchenko S, Roteli-Martins C, Nerovjna R, Kljukina L, Tatti S, Branovskaja M, Branca M, Grunjberga V, Erzen M, Juschenko A, Serpa Hammes L, Podistov J, Costa S, Syrjänen S; NIS Study Research Group; LAMS Study Research Group. Syrjänen K, et al. Eur J Gynaecol Oncol. 2012;33(1):5-14. Eur J Gynaecol Oncol. 2012. PMID: 22439398
Longitudinal outcomes of high-risk human papillomavirus (HPV) infections as competing-risks events following cervical HPV test at baseline visit in the NIS-LAMS cohort.
Syrjänen K, Shabalova I, Sarian L, Naud P, Longatto-Filho A, Derchain S, Kozachenko V, Zakharchenko S, Roteli-Martins C, Nerovjna R, Kljukina L, Tatti S, Branovskaja M, Branca M, Grunjberga V, Erzen M, Juschenko A, Hammes LS, Podistov J, Costa S, Syrjänen S; NIS Study Research Group; LAMS Study Research Group. Syrjänen K, et al. Eur J Gynaecol Oncol. 2012;33(4):341-52. Eur J Gynaecol Oncol. 2012. PMID: 23091888
Competing-risks regression models in analysis of biomarkers as predictors of high-risk human papillomavirus (HPV) infection outcomes and incident CIN in the LAMS cohort.
Syrjänen S, Longhato-Filho A, Sarian LO, Naud P, Derchain S, Rottelli-Martins C, Tatti S, Branca M, Eržen M, Hammes LS, Matos J, Gontijo R, Bragança J, Arlindo FC, Maeda MY, Costa S, Syrjänen K. Syrjänen S, et al. Among authors: sarian lo. Int J Gynecol Pathol. 2013 Jul;32(4):406-15. doi: 10.1097/PGP.0b013e31826739b1. Int J Gynecol Pathol. 2013. PMID: 23722514 Clinical Trial.
Comparing PAP smear cytology, aided visual inspection, screening colposcopy, cervicography and HPV testing as optional screening tools in Latin America. Study design and baseline data of the LAMS study.
Syrjänen K, Naud P, Derchain S, Roteli-Martins C, Longatto-Filho A, Tatti S, Branca M, Erzen M, Hammes LS, Matos J, Gontijo R, Sarian L, Braganca J, Arlindo FC, Maeda MY, Lörincz A, Dores GB, Costa S, Syrjänen S. Syrjänen K, et al. Anticancer Res. 2005 Sep-Oct;25(5):3469-80. Anticancer Res. 2005. PMID: 16101165 Free article. Clinical Trial.
151 results